Who
Ran Nussbaum
Director
Company insider
Files Form 4 as: Director, LB Pharmaceuticals; Director and 10% owner, Keros Therapeutics; Director, UroGen Pharma; Director, Eloxx Pharmaceuticals; Director, Prevail Therapeutics; Director, Arqule; Director, Kite Pharma.
In numbers
- Trades disclosed
- 170
- Buys
- 12
- Sells
- 4
- Bought
- $40.0M
- Sold
- $28.6M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 25 Jun 2014
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 Sep 2025filed 16 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —10,000,000 | filing |
| 12 Sep 2025filed 16 Sep 2025 | LBRX LB PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —411,681 | filing |
| 12 Sep 2025filed 16 Sep 2025 | LBRX LB PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $15.0M1,000,000 at $15.00 | filing |
| 10 Sep 2025filed 12 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,449 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,250 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 29 Nov 2022filed 30 Nov 2022 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code X | —3,539 at $0.00 | filing |
| 29 Nov 2022filed 30 Nov 2022 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code X | —1,723 at $0.00 | filing |
| 29 Nov 2022filed 30 Nov 2022 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code X | —1,914 at $0.00 | filing |
| 29 Nov 2022filed 30 Nov 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code X | —3,539 at $0.00 | filing |
| 29 Nov 2022filed 30 Nov 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code X | —1,723 at $0.00 | filing |
| 29 Nov 2022filed 30 Nov 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code X | —1,914 at $0.00 | filing |
| 21 Oct 2022filed 28 Feb 2023 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —32,723 at $0.00 | filing |
| 21 Oct 2022filed 28 Feb 2023 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,276 at $0.00 | filing |
| 21 Oct 2022filed 28 Feb 2023 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | $285K47,999 at $5.94 | filing |
| 21 Oct 2022filed 25 Oct 2022 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —32,723 at $0.00 | filing |
News
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical OfficerELOX · prnewswire.com · 20 Oct 2026Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of DirectorsELOX · prnewswire.com · 19 Oct 2026Head to Head Review: Cumberland Pharmaceuticals (NASDAQ:CPIX) & Eloxx Pharmaceuticals (NASDAQ:ELOX)ELOX · dailypolitical.com · 17 Oct 2026LB Pharmaceuticals to Participate in Upcoming Investor EventsLBRX · manilatimes.net · 15 Oct 2026LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 7% – What's Next?LBRX · dailypolitical.com · 12 Oct 2026Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)LBRX · manilatimes.net · 9 Oct 2026MacroGenics (NASDAQ:MGNX) vs. Keros Therapeutics (NASDAQ:KROS) Head to Head ReviewKROS · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Ran Nussbaum; 8 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.